• 论著 • 上一篇    下一篇

HLA-G和IL-10在非小细胞肺癌组织中的表达

宋新宇1,陈世雄1,曾凡军1,高宝安1,杨卫兵2   

  1. 1. 宜昌市中心人民医院
    2. 华中科技大学同济医学院附属协和医院
  • 收稿日期:2011-01-05 修回日期:2011-06-20 出版日期:2011-11-15 发布日期:2011-11-15
  • 通讯作者: 宋新宇

Expression of the Human Leukocyte Antigen G and Interleukin-10 in Human Non-Small Cell Lung Cancer

  • Received:2011-01-05 Revised:2011-06-20 Published:2011-11-15 Online:2011-11-15

摘要: 摘要 目的:探讨HLA-G和IL-10在非小细胞肺癌组织中的表达状况及与各因素的关系。方法:以经手术切除的38例非小细胞肺癌组织标本为病例组,12例正常肺组织为对照组,通过免疫组化的方法检测两组标本的HLA-G和IL-10蛋白的表达水平,并对两者进行相关分析。结果:38例非小细胞肺癌组织标本中有28例(74%)HLA-G表达阳性,有30例(79%)IL-10表达阳性。 HLA-G的表达水平与肺癌的TNM分期呈正相关(rs=0.443 , P<0.01 )。IL-10的表达水平与各临床病理因素无关。正常肺组织中无HLA-G和IL-10的表达。28例HLA-G阳性的肺癌组织中有25例(93%)IL-10阳性,两者呈正相关(rs=0.424 , P<0.01)。结论:HLA-G和IL-10在肿瘤中相互作用形成了一个自分泌的恶性循环,而它破坏宿主的免疫功能最终使得肿瘤逃脱宿主免疫监视。

关键词: 非小细胞肺癌, HLA-G, IL-10, 免疫抑制

Abstract: Abstract Objective: To investigate the expression of the human leukocyte antigen G (HLA-G) and interleukin-10 (IL-10) in non-small cell lung cancer (NSCLC),and the correlation between expressions of them. Methods: The expressions of HLA-G and IL-10 were detected using immunohistochemical method in surgically resected specimens from 38 patients with NSCLC (patient group) and normal lung tissues from 12 patients without lung cancer (control group). Results: There were 28 positive expressions of HLA-G (74%) and 30 IL-10 protein expressions (79%) in specimens of NSCLCs, respectively. A positive correlation was found between HLA-G expression and stages of TNM (rs=0.443, P<0.01). No significance correlation was found between IL-10 expression and clinicopathological factors. There was no HLA-G and IL-10 protein expression in normal lung tissues. Furthermore, IL-10 protein expression was demonstrated in 25 (93%) of 28 HLA-G positive cases. There was a positive correlation between them (rs=0.424, P< 0.01). Conclusion: HLA-G and IL-10 form a vicious autocrine circle of immune response abrogation in cancer to help tumor evade immune surveillance.

Key words: non-small-cell lung cancer, HLA-G, IL-10, immunosuppressive